biostudies-literatureNan FYZhenjiang Clinical Research Center of HematologyMedical Innovation Team of Jiangsu ProvinceScientific Research Project of The Fifth 169 Project of ZhenjianNational Natural Science Foundation of ChinaSocial Development Foundation of Zhenjiang5283-5296https://www.ebi.ac.uk/biostudies/studies/S-EPMC8335806biostudies-literatureUnknown10(15)It was previously reported that PRR34-AS1 was overexpressed in some solid tumors. PRR34-AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real-time quantitative PCR (RQ-PCR) to explore the expression characteristics of PRR34-AS1 in AML. In addition, the correlation between the expression of PRR34-AS1 and clinical prognosis of AML was determined. The findings of this study indicated that high PRR34-AS1 expression was bound up with shorter overall survival (OS) in AML patients (p = 0.002). Moreover, patients with high expression of PRR34-AS1 had significantly lower complete remission (CR) rate compared with those with low expression of PRR34-AS1 after induction chemotherapy. FurtheCancer medicineAbnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia.PMC833580681900166SH2019065SH2019067SS20180098197011881900163CXTDB2017002Qian JGu YNan FYLin JZhou JDMa JCSun GKLeng JYXu ZJZhang TJfalseAbnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia.It was previously reported that PRR34-AS1 was overexpressed in some solid tumors. PRR34-AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real-time quantitative PCR (RQ-PCR) to explore the expression characteristics of PRR34-AS1 in AML. In addition, the correlation between the expression of PRR34-AS1 and clinical prognosis of AML was determined. The findings of this study indicated that high PRR34-AS1 expression was bound up with shorter overall survival (OS) in AML patients (p = 0.002). Moreover, patients with high expression of PRR34-AS1 had significantly lower complete remission (CR) rate compared with those with low expression of PRR34-AS1 after induction chemotherapy. Furthe2021-01-01T00:00:00Z2021 Aug2026-05-08T16:57:33.414Z2022-02-11T06:05:04.27ZS-EPMC83358063422724810.1002/cam4.4085